Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Edwards Lifesciences Corp Reaffirms FY 2012 Gudeance; Issues FY 2013 Gudeance In Line With Analysts' Estimates


Tuesday, 4 Dec 2012 09:00am EST 

Edwards Life sciences Corp reaffirmed its fiscal 2012 sales and earnings guidance, which includes diluted earnings per share of $2.54 to $2.58, excluding special items. The Company will also detail its expectations for fiscal 2013, including total sales of $2.1 billion to $2.2 billion. Excluding special items, Edwards expects diluted earnings per share of $3.21 to $3.31. According to I/B/E/S Estimates, analysts are expecting the Company to report revenues of $1.89 billion and EPS of $2.56 for fiscal 2012; revenues of $2.13 billion and EPS of $3.21 for fiscal 2013. 

Company Quote

87.94
-0.21 -0.24%
11 Jul 2014